Nitric oxide and stroke

http://www.nottingham.ac.uk/~nszwww/enos//
The 'Efficacy of Nitric Oxide in Stroke' (ENOS) study is a collaborative, international, multicentre, prospective, randomised, single-blind, blinded endpoint, parallel-group, controlled trial designed to test the safety and efficacy of:
(i) transdermal glyceryl trinitrate (a nitric oxide donor) or control; and
(ii) continuing or temporarily stopping prior anti-hypertensive medication.
3,500+ patients with acute ischaemic or haemorrhagic stroke will be enrolled within 48 hours of the onset of stroke and treatment will be given for 7 days. The primary outcome is shift in death or dependency (modified Rankin Scale) determined at 90 days by observers blinded to treatment.
Power point presentation, V1.0 (Powerpoint, size=3.9MB)
http://www.nottingham.ac.uk/~nszwww/enos//enostalkgenericv10.ppt
Brief Information for patients & relatives about the trial, V1.1 (PDF file, MREC approved)
http://www.nottingham.ac.uk/~nszwww/enos//enosinfopatrelv11.pdf
Full information for patients, V2.11 (PDF file, MREC approved)
http://www.nottingham.ac.uk/~nszwww/enos//enospisv211.pdf
Nobel prize is awarded for NO discovery
http://circ.ahajournals.org/cgi/content/full/98/22/2365
Nitric oxide was named "Molecule of the Year" in 1992 by the journal Science, but it took another 6 years for those responsible for the major discoveries surrounding it to win the Nobel Prize. Three US scientists—Robert F. Furchgott, PhD, Louis J. Ignarro, PhD, and Ferid Murad, MD, PhD—will receive the 1998 Nobel Prize for Physiology and Medicine on December 10, 1998, in Stockholm, Sweden.
The discovery of nitric oxide's signaling role in the cardiovascular and nervous systems is now nearly 20 years old, but its clinical use is only beginning. Dr Furchgott, a distinguished professor of pharmacology at the State University of New York (SUNY) at Brooklyn, began the studies that led to the identification of nitric oxide as a biological agent in 1980. At that time, he was trying to reconcile the contradictory effects drugs had on blood vessels. He concluded that endothelial cells produce an unknown signal molecule that makes vascular smooth muscle cells relax. He called the signal molecule EDRF, or endothelium-derived relaxing factor.
In unrelated experiments, Dr Murad, now chairman of the integrative biology department at the University of Texas Medical School at Houston, was analyzing how nitroglycerin works. In 1977, while at the University of Virginia, he found that nitrates release nitric oxide, which relaxes smooth muscle cells, resulting in vasodilation. He was fascinated that the colorless, odorless gas could act as a signaling molecule.
Dr Ignarro, now a professor of pharmacology at UCLA School of Medicine in Los Angeles, California, through a series of analyses concluded in 1986 that EDRF was identical to nitric oxide. His work, done independently and together with that of Dr Furchgott, prompted an increase in research activities in many areas of the world.

I have no idea if this is just for acute or rehab. I was taking NO prior to the event, a combination of L-Carnatine and L-Arginine, but I have quit due to the size of the pills. Talk to your doctor on this.